Merrimack Pharmaceuticals Inc. Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Exemestane in Breast Cancer

Published: May 23, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2 randomized, double blind clinical trial of MM-121 in combination with exemestane in postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+), HER2-negative breast cancer. MM-121, a fully human monoclonal antibody that targets ErbB3, is being developed in collaboration with Sanofi.

Help employers find you! Check out all the jobs and post your resume.

Back to news